Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.


TSX:MSCL - Post by User

Comment by 48thHighlanderon Jul 10, 2018 3:40pm
127 Views
Post# 28295316

RE:Just re-read this...

RE:Just re-read this...

Market size of iCo-019 (Oral Amp B) - Billions!!!!Quote from ICO NR in the past:

 

DoubleBank rates ICO.v as a Strong Buy under 25 cents (CAD) and an extremely 

RARE OPPORTUNITY seated in a dull Market Environment - BUY ICO / ICOTF



“Given our significant progress in contract manufacturing and pre-clinical development we have a highly differentiated Oral Amp B lead candidate rapidly making its way into the clinic," stated Andrew Rae, President and CEO. "Assuming clinical data reflects meaningful pre-clinical outcomes we believe we may address anti-fungal markets in excess of a billion dollars with an asset that makes administration far more accessible to a broad population."
<< Previous
Bullboard Posts
Next >>